|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||48.08 - 48.82|
|52 Week Range||36.81 - 50.24|
|PE Ratio (TTM)||11.63|
|Dividend & Yield||1.64 (3.39%)|
|1y Target Est||N/A|
The settlement came after an unusual lawsuit by Sanofi, a competitor to Mylan, which alleged anti-competitive tactics.
TRENTON, N.J. (AP) — EpiPen maker Mylan has finalized a $465 million government agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade — charges brought after rival Sanofi filed a whistleblower lawsuit and tipped off the government.
Mylan NV will pay $465 million fine to settle claims brought by the U.S. Justice Department that it overcharged the government for its emergency allergy drug, EpiPen. French drug company Sanofi, the parent company of the state’s largest biotech employer, Sanofi Genzyme (SNY), first brought the matter to the attention of the U.S. Attorney’s Office in 2014 because it was selling a competing epinephrine auto-injector drug called AUVI-Q. In 2016, Sanofi filed a complaint in Massachusetts federal court against Mylan under the False Claims Act, which permits private parties to sue on behalf of the government and to receive a share of any recovery.